Skip to main content
OpenTrials
Completed

NCT Number: NCT02308592

Patient Decision Aid for Antidepressant Use in Pregnancy

The purpose of this pilot study is to examine the feasibility of conducting a multi-site randomized controlled trial whose aim will be to evaluate the effectiveness of a Patient Decision Aid (PDA) for antidepressant use in pregnancy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Women's College Hospital

Toronto, Ontario, M5S 1B2, Canada

About this study

Depression in pregnancy is common, affecting up to 10% of women and represents serious risk to mother and infant. Unfortunately, antidepressant medication, a first-line treatment for depression in pregnancy, also comes with risks, making this a complex decision. Clinical care appears to be insufficient for ensuring that women make decisions that are consistent with their own values and with which they feel satisfied. Patient decision support tools can address such barriers. We have created a patient decision aid (PDA) that has the potential to improve the decision-making process for women regarding antidepressant use in pregnancy in conjunction with clinical care. The overall objective of this project is to inform the development of a larger, international RCT to assess the efficacy of our PDA for antidepressant use in pregnancy. To achieve this objective, we will assess the feasibility of our clinical trial protocol to evaluate the PDA and determine the preliminary effect size for a larger multi-site efficacy study. The primary outcome for this pilot study is the feasibility of conducting a large randomized controlled trial to evaluate the efficacy of the PDA. This includes feasibility (how well the trial protocol can be implemented), acceptability (usability and tolerability of the intervention) and adherence (the degree to which the trial protocol is followed). We hypothesize that our protocol will be feasible, that the PDA will have a high degree of acceptability, and that adherence to the protocol will be high.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Are females aged >18 years old, and
  • Are either planning a pregnancy OR are <30 weeks gestation at enrollment, and
  • Have been offered to start or continue SSRI or SNRI anti-depressant medication as a treatment option for depression by their clinical provider at one of the study sites, and
  • Have moderate-to-high decisional conflict (score of >25 on the Decisional Conflict Scale)

Exclusion criteria

  • Have had alcohol or substance abuse or dependence in the previous 12 months, or
  • Have active suicidal ideation or psychosis, or
  • Are incapable of consenting to participation, or
  • Have any major obstetrical complications or fetal cardiac anomaly in the current or in a past pregnancy (as this changes the risk/benefit ratio discussion in regards to antidepressant use), or
  • Are unable to read or unable to speak or understand English and do not have someone that can read the PDA to them, or
  • Have a visual impairment that would prevent them from being able to view the website.

Treatment and study plan

Electronic patient decision aid

Behavioral

The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:

  • Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;
  • (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and
  • A summary section that outlines the information reviewed and which benefits and risks they deemed most important.

Standard Resource Sheet

Behavioral

Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).

Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization.

Primary outcomes

  1. Recruitment Rate

    Time frame: Up to one year from when the study starts enrolling participants

    Feasibility: Number of participants recruited into the study over Number of eligible patients

Secondary outcomes

  1. Decisional Conflict Scale

    Time frame: Baseline (pre-randomization)

  2. Knowledge about antidepressant treatment in pregnancy

    Time frame: Baseline (pre-randomization)

  3. Edinburgh Postnatal Depression Scale

    Time frame: Baseline (pre-randomization)

  4. Spielburg State-Trait Anxiety Inventory

    Time frame: Baseline (pre-randomization)

  5. Edinburgh Postnatal Depression Scale

    Time frame: 4 Weeks post-randomization

  6. Edinburgh Postnatal Depression Scale

    Time frame: 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), only for participants who are seeing specialty psychiatric services

  7. Spielburg State-Trait Anxiety Inventory

    Time frame: 4 Weeks post-randomization

  8. Spielburg State-Trait Anxiety Inventory

    Time frame: 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), only for participants who are seeing specialty psychiatric services

  9. Decisional Conflict Scale

    Time frame: 4 Weeks post-randomization

  10. Knowledge about antidepressant treatment in pregnancy

    Time frame: 4 Weeks post-randomization

  11. PDA Acceptability Questionnaire

    Time frame: 4 Weeks post-randomization

  12. Provider Perspective Survey

    Time frame: After all other participant data has been collected

  13. Treatment Decision(s)

    Time frame: Baseline (pre-randomization)

  14. Treatment Decision(s)

    Time frame: 4 Weeks post-randomization

  15. Treatment Decision(s)

    Time frame: 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), only for participants who are seeing specialty psychiatric services

  16. Time between recruitment to first log-in to the study website

    Time frame: 4 weeks post-randomization

  17. Self-reported satisfaction with the PDA by the participants

    Time frame: 4 Weeks post-randomization

  18. Provider's perspective on the utility of the PDA in clinical practice

    Time frame: After all participant data has been collected

  19. Study Website Usage

    Time frame: 4 Weeks post-randomization

    Composite measure comprised of: (1) number of participants who complete the PDA, (2) length of time required to complete the PDA, (3) number of log ins, (4) number of times the PDA is completed per participant, (5) total number of webpages viewed).

  20. Number of participants who follow-up with their physician during the intended timeline

    Time frame: 4 weeks post-randomization, only for participants who are seeing specialty psychiatric services

  21. The rate of follow-up data collection

    Time frame: 4 Weeks post-randomization

  22. The rate of follow-up data collection

    Time frame: 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), OR at 4 weeks post-randomization for women who are NOT seeing specialty perinatal psychiatry services

Sponsors and collaborators

Lead sponsor

Women's College Hospital

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)
  • Ontario Ministry of Health and Long Term Care

Registry information

Official study title

Patient Decision Aid (PDA) for Antidepressant Use In Pregnancy

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Dec 4, 2014
Registry last updated
May 12, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.